Details of the Drug Combination

General Information of Drug Combination (ID: DC3TZAV)

Drug Combination Name
Gefitinib Cyclophosphamide
Indication
Disease Entry Status REF
Chronic myelogenous leukemia Investigative [1]
Component Drugs Gefitinib   DM15F0X Cyclophosphamide   DM4O2Z7
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL
High-throughput Screening Result Testing Cell Line: K-562
Zero Interaction Potency (ZIP) Score: 2.68
Bliss Independence Score: 1.89
Loewe Additivity Score: 0.29
LHighest Single Agent (HSA) Score: 2.46

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Gefitinib
Disease Entry ICD 11 Status REF
Colon adenocarcinoma N.A. Approved [2]
Glioblastoma 2A00 Approved [2]
Lung cancer 2C25.0 Approved [2]
Non-small-cell lung cancer 2C25.Y Approved [2]
Rectal adenocarcinoma 2B92 Approved [2]
Rectum mucinous adenocarcinoma N.A. Approved [2]
Solid tumour/cancer 2A00-2F9Z Approved [3]
Head and neck cancer 2D42 Phase 3 [3]
Urethral cancer 2C93 Phase 2 [3]
Colon cancer 2B90.Z Investigative [2]
Colon mucinous adenocarcinoma N.A. Investigative [2]
Gefitinib Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Epidermal growth factor receptor (EGFR) TTGKNB4 EGFR_HUMAN Inhibitor [11]
------------------------------------------------------------------------------------
Gefitinib Interacts with 4 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [12]
Breast cancer resistance protein (ABCG2) DTI7UX6 ABCG2_HUMAN Substrate [13]
Organic anion transporting polypeptide 1B1 (SLCO1B1) DT3D8F0 SO1B1_HUMAN Substrate [14]
Organic anion transporting polypeptide 1B3 (SLCO1B3) DT9C1TS SO1B3_HUMAN Substrate [14]
------------------------------------------------------------------------------------
Gefitinib Interacts with 3 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [15]
Cytochrome P450 2D6 (CYP2D6) DECB0K3 CP2D6_HUMAN Metabolism [16]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Metabolism [15]
------------------------------------------------------------------------------------
Gefitinib Interacts with 103 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Broad substrate specificity ATP-binding cassette transporter ABCG2 (ABCG2) OTW8V2V1 ABCG2_HUMAN Increases ADR [17]
Epidermal growth factor receptor (EGFR) OTAPLO1S EGFR_HUMAN Decreases Response To Substance [18]
Sulfhydryl oxidase 1 (QSOX1) OT4ZPK4P QSOX1_HUMAN Increases Expression [19]
Growth arrest and DNA damage-inducible protein GADD45 gamma (GADD45G) OT8V1J4M GA45G_HUMAN Decreases Expression [19]
Interferon alpha-inducible protein 6 (IFI6) OTWOOAM4 IFI6_HUMAN Decreases Expression [19]
Fibroblast growth factor 6 (FGF6) OTRJ679P FGF6_HUMAN Increases Expression [19]
Ski oncogene (SKI) OT4KJ8F6 SKI_HUMAN Increases Expression [19]
Erythropoietin receptor (EPOR) OTUIOEU3 EPOR_HUMAN Increases Expression [19]
Nuclear factor NF-kappa-B p105 subunit (NFKB1) OTNRRD8I NFKB1_HUMAN Decreases Expression [19]
Tumor necrosis factor receptor superfamily member 1B (TNFRSF1B) OTDS2EAR TNR1B_HUMAN Decreases Expression [19]
Growth arrest and DNA damage-inducible protein GADD45 alpha (GADD45A) OTDRV63V GA45A_HUMAN Increases Expression [19]
Cytochrome P450 2F1 (CYP2F1) OTY3HJH1 CP2F1_HUMAN Decreases Expression [19]
Replication protein A 70 kDa DNA-binding subunit (RPA1) OT76POLP RFA1_HUMAN Increases Expression [19]
Adenosine receptor A1 (ADORA1) OTI7X39E AA1R_HUMAN Decreases Expression [19]
14-3-3 protein sigma (SFN) OTLJCZ1U 1433S_HUMAN Decreases Expression [19]
DNA mismatch repair protein Mlh1 (MLH1) OTG5XDD8 MLH1_HUMAN Decreases Expression [19]
Glycine--tRNA ligase (GARS1) OT5B6R9Y GARS_HUMAN Increases Expression [19]
Epidermal growth factor receptor substrate 15 (EPS15) OT7NPP8U EPS15_HUMAN Increases Expression [19]
Neuronal pentraxin-2 (NPTX2) OT3SSJDP NPTX2_HUMAN Decreases Expression [19]
Leptin receptor (LEPR) OT9H7G0C LEPR_HUMAN Decreases Expression [19]
Neural retina-specific leucine zipper protein (NRL) OT65MFKQ NRL_HUMAN Decreases Expression [19]
Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-2 (GNB2) OT3JPRCQ GBB2_HUMAN Decreases Expression [19]
Retinal guanylyl cyclase 1 (GUCY2D) OT81UJI0 GUC2D_HUMAN Decreases Expression [19]
Cell growth regulator with RING finger domain protein 1 (CGRRF1) OTLMNRCL CGRF1_HUMAN Increases Expression [19]
Dual specificity protein phosphatase 9 (DUSP9) OTZZWEQL DUS9_HUMAN Decreases Expression [19]
Bile salt export pump (ABCB11) OTRU7THO ABCBB_HUMAN Decreases Activity [20]
Retinoblastoma-associated protein (RB1) OTQJUJMZ RB_HUMAN Decreases Expression [21]
Glycogen synthase kinase-3 beta (GSK3B) OTL3L14B GSK3B_HUMAN Decreases Expression [21]
Cyclin-dependent kinase 6 (CDK6) OTR95N0X CDK6_HUMAN Decreases Expression [21]
Telomerase reverse transcriptase (TERT) OT085VVA TERT_HUMAN Decreases Expression [22]
Baculoviral IAP repeat-containing protein 5 (BIRC5) OTILXZYL BIRC5_HUMAN Decreases Expression [23]
Ubiquitin-like modifier-activating enzyme ATG7 (ATG7) OTVT4YA1 ATG7_HUMAN Increases Expression [24]
Myc proto-oncogene protein (MYC) OTPV5LUK MYC_HUMAN Decreases Expression [25]
Tumor necrosis factor (TNF) OT4IE164 TNFA_HUMAN Decreases Expression [7]
Interleukin-1 beta (IL1B) OT0DWXXB IL1B_HUMAN Increases Expression [26]
HLA class II histocompatibility antigen, DRB1 beta chain (HLA-DRB1) OTRGGIFP DRB1_HUMAN Affects Expression [27]
Estrogen receptor (ESR1) OTKLU61J ESR1_HUMAN Decreases Phosphorylation [28]
Receptor tyrosine-protein kinase erbB-2 (ERBB2) OTOAUNCK ERBB2_HUMAN Decreases Phosphorylation [29]
HLA class II histocompatibility antigen, DO alpha chain (HLA-DOA) OTZE5Q7R DOA_HUMAN Affects Expression [27]
Heat shock protein HSP 90-alpha (HSP90AA1) OTLG1WPK HS90A_HUMAN Increases Secretion [26]
Insulin-like growth factor 1 receptor (IGF1R) OTXJIF13 IGF1R_HUMAN Increases Phosphorylation [30]
High mobility group protein B1 (HMGB1) OT4B7CPF HMGB1_HUMAN Increases Secretion [26]
Poly polymerase 1 (PARP1) OT310QSG PARP1_HUMAN Increases Cleavage [31]
Heat shock 70 kDa protein 1A (HSPA1A) OTKGIE76 HS71A_HUMAN Increases Secretion [26]
C-C motif chemokine 2 (CCL2) OTAD2HEL CCL2_HUMAN Increases Secretion [32]
Matrix metalloproteinase-9 (MMP9) OTB2QDAV MMP9_HUMAN Decreases Expression [7]
Platelet endothelial cell adhesion molecule (PECAM1) OTXOM4D9 PECA1_HUMAN Decreases Expression [7]
Ribosomal protein S6 kinase beta-1 (RPS6KB1) OTAELNGX KS6B1_HUMAN Decreases Phosphorylation [24]
Alanine aminotransferase 1 (GPT) OTOXOA0Q ALAT1_HUMAN Increases Secretion [33]
G1/S-specific cyclin-D1 (CCND1) OT8HPTKJ CCND1_HUMAN Decreases Expression [18]
DnaJ homolog subfamily B member 1 (DNAJB1) OTCOSEVH DNJB1_HUMAN Increases Secretion [26]
Mitogen-activated protein kinase 3 (MAPK3) OTCYKGKO MK03_HUMAN Decreases Expression [34]
Mitogen-activated protein kinase 1 (MAPK1) OTH85PI5 MK01_HUMAN Decreases Expression [34]
Caspase-1 (CASP1) OTZ3YQFU CASP1_HUMAN Increases Activity [26]
G1/S-specific cyclin-D3 (CCND3) OTNKPQ22 CCND3_HUMAN Decreases Expression [18]
HLA class I histocompatibility antigen, alpha chain F (HLA-F) OT76CM19 HLAF_HUMAN Affects Expression [27]
RAC-alpha serine/threonine-protein kinase (AKT1) OT8H2YY7 AKT1_HUMAN Decreases Phosphorylation [35]
Cyclin-dependent kinase inhibitor 1 (CDKN1A) OTQWHCZE CDN1A_HUMAN Decreases Expression [23]
Serine/threonine-protein kinase mTOR (MTOR) OTHH8KU7 MTOR_HUMAN Decreases Phosphorylation [24]
Cyclin-dependent kinase 4 inhibitor B (CDKN2B) OTAG24N1 CDN2B_HUMAN Increases Expression [25]
Mitogen-activated protein kinase 8 (MAPK8) OTEREYS5 MK08_HUMAN Decreases Phosphorylation [7]
Cyclin-dependent kinase inhibitor 1B (CDKN1B) OTNY5LLZ CDN1B_HUMAN Increases Expression [18]
Tumor necrosis factor ligand superfamily member 6 (FASLG) OTZARCHH TNFL6_HUMAN Increases Response To Substance [36]
Cytochrome c (CYCS) OTBFALJD CYC_HUMAN Affects Localization [31]
Transcription factor E2F1 (E2F1) OTLKYBBC E2F1_HUMAN Decreases Expression [22]
Caveolin-1 (CAV1) OTEZUR1L CAV1_HUMAN Increases Expression [34]
Sequestosome-1 (SQSTM1) OTGY5D5J SQSTM_HUMAN Decreases Expression [37]
Kelch-like ECH-associated protein 1 (KEAP1) OTFHOD0C KEAP1_HUMAN Increases Expression [38]
Caspase-8 (CASP8) OTA8TVI8 CASP8_HUMAN Increases Cleavage [36]
Cytochrome P450 1B1 (CYP1B1) OTYXFLSD CP1B1_HUMAN Decreases Activity [39]
MHC class I polypeptide-related sequence B (MICB) OTS2DVDW MICB_HUMAN Increases Expression [40]
MHC class I polypeptide-related sequence A (MICA) OTPEIEAR MICA_HUMAN Increases Expression [40]
Estrogen receptor beta (ESR2) OTXNR2WQ ESR2_HUMAN Increases Expression [41]
Serine protease HTRA1 (HTRA1) OTR8ACBF HTRA1_HUMAN Increases Expression [42]
Major histocompatibility complex class I-related gene protein (MR1) OTZU3XX7 HMR1_HUMAN Affects Expression [27]
Autophagy protein 5 (ATG5) OT4T5SMS ATG5_HUMAN Increases Expression [24]
Transcription factor SOX-17 (SOX17) OT9H4WWE SOX17_HUMAN Decreases Localization [43]
MARVEL domain-containing protein 1 (MARVELD1) OT5CPOJE MALD1_HUMAN Decreases Response To Substance [44]
GTPase KRas (KRAS) OT78QCN8 RASK_HUMAN Decreases Response To Substance [45]
Zinc finger protein SNAI2 (SNAI2) OT7Y8EJ2 SNAI2_HUMAN Affects Response To Substance [46]
Membrane-associated progesterone receptor component 1 (PGRMC1) OTBE6WAC PGRC1_HUMAN Decreases Response To Substance [47]
Cytochrome P450 1A1 (CYP1A1) OTE4EFH8 CP1A1_HUMAN Increases Response To Substance [48]
Glutamate--cysteine ligase catalytic subunit (GCLC) OTESDI4D GSH1_HUMAN Affects Response To Substance [49]
RNA-binding protein 7 (RBM7) OTFIWTMF RBM7_HUMAN Affects Response To Substance [49]
Cell death regulator Aven (AVEN) OTGIN5YK AVEN_HUMAN Affects Response To Substance [49]
Forkhead box protein O3 (FOXO3) OTHXQG4P FOXO3_HUMAN Increases Response To Substance [50]
Phospholipase B-like 1 (PLBD1) OTHYEB4W PLBL1_HUMAN Affects Response To Substance [49]
Cellular tumor antigen p53 (TP53) OTIE1VH3 P53_HUMAN Affects Response To Substance [51]
Securin (PTTG1) OTIMYS4W PTTG1_HUMAN Decreases Response To Substance [31]
Amphiregulin (AREG) OTJFOR67 AREG_HUMAN Decreases Response To Substance [49]
Pleckstrin homology-like domain family A member 2 (PHLDA2) OTMV9DPP PHLA2_HUMAN Affects Response To Substance [49]
Aurora kinase A (AURKA) OTMX0HYT AURKA_HUMAN Decreases Response To Substance [51]
DNA excision repair protein ERCC-1 (ERCC1) OTNPYQHI ERCC1_HUMAN Affects Response To Substance [10]
Bcl-2-like protein 11 (BCL2L11) OTNQQWFJ B2L11_HUMAN Increases Response To Substance [52]
Ceramide transfer protein (CERT1) OTNUCNHX CERT_HUMAN Affects Response To Substance [49]
DNA repair protein RAD51 homolog 1 (RAD51) OTNVWGC1 RAD51_HUMAN Affects Response To Substance [53]
Oncostatin-M-specific receptor subunit beta (OSMR) OTORWHPL OSMR_HUMAN Affects Response To Substance [49]
Protransforming growth factor alpha (TGFA) OTPD1LL9 TGFA_HUMAN Decreases Response To Substance [54]
Dual specificity protein phosphatase 3 (DUSP3) OTPJX9B4 DUS3_HUMAN Affects Response To Substance [49]
Transcription factor p65 (RELA) OTUJP9CN TF65_HUMAN Decreases Response To Substance [51]
Pericentrin (PCNT) OTW4Z65J PCNT_HUMAN Decreases Response To Substance [47]
Coronin-1C (CORO1C) OTXDF9T3 COR1C_HUMAN Affects Response To Substance [49]
Ribonucleoside-diphosphate reductase large subunit (RRM1) OTXGQOR9 RIR1_HUMAN Affects Response To Substance [10]
------------------------------------------------------------------------------------
⏷ Show the Full List of 103 DOT(s)
Indication(s) of Cyclophosphamide
Disease Entry ICD 11 Status REF
Advanced cancer 2A00-2F9Z Approved [4]
Central nervous system neoplasm N.A. Approved [4]
Glioblastoma 2A00 Approved [4]
Immunodeficiency 4A00-4A85 Approved [4]
Inflammatory breast cancer 2C62 Approved [4]
Lupus nephritis 4A40.0Y Approved [4]
Lymphoma 2A80-2A86 Approved [4]
Multiple sclerosis 8A40 Approved [4]
Mycosis fungoides 2B01 Approved [4]
Plasma cell myeloma 2A83.1 Approved [4]
Solid tumour/cancer 2A00-2F9Z Approved [5]
Classic Hodgkin lymphoma N.A. Investigative [4]
Neuroblastoma 2D11.2 Investigative [4]
Retinoblastoma 2D02.2 Investigative [4]
Scleroderma 4A42 Investigative [4]
Cyclophosphamide Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Human Deoxyribonucleic acid (hDNA) TTUTN1I NOUNIPROTAC Modulator [61]
------------------------------------------------------------------------------------
Cyclophosphamide Interacts with 1 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
Multidrug resistance-associated protein 4 (ABCC4) DTCSGPB MRP4_HUMAN Substrate [62]
------------------------------------------------------------------------------------
Cyclophosphamide Interacts with 8 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [63]
Cytochrome P450 2A6 (CYP2A6) DEJVYAZ CP2A6_HUMAN Metabolism [64]
Cytochrome P450 3A7 (CYP3A7) DERD86B CP3A7_HUMAN Metabolism [65]
Cytochrome P450 2C18 (CYP2C18) DEZMWRE CP2CI_HUMAN Metabolism [64]
Cytochrome P450 2C8 (CYP2C8) DES5XRU CP2C8_HUMAN Metabolism [66]
Cytochrome P450 2C9 (CYP2C9) DE5IED8 CP2C9_HUMAN Metabolism [67]
Cytochrome P450 2B6 (CYP2B6) DEPKLMQ CP2B6_HUMAN Metabolism [68]
Mephenytoin 4-hydroxylase (CYP2C19) DEGTFWK CP2CJ_HUMAN Metabolism [69]
------------------------------------------------------------------------------------
⏷ Show the Full List of 8 DME(s)
Cyclophosphamide Interacts with 225 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Cytochrome P450 2C8 (CYP2C8) OTHCWT42 CP2C8_HUMAN Increases Activity [70]
Cytochrome P450 2C18 (CYP2C18) OTY687L9 CP2CI_HUMAN Increases Activity [70]
Cytochrome P450 3A4 (CYP3A4) OTQGYY83 CP3A4_HUMAN Increases Expression [71]
Cytochrome P450 2B6 (CYP2B6) OTOYO4S7 CP2B6_HUMAN Increases Hydroxylation [72]
Glucose-6-phosphate 1-dehydrogenase (G6PD) OT300SMK G6PD_HUMAN Increases ADR [55]
Cytochrome P450 2D6 (CYP2D6) OTZJC802 CP2D6_HUMAN Increases Metabolism [73]
Cholinesterase (BCHE) OTOH3WQ9 CHLE_HUMAN Decreases Activity [74]
Actin, cytoplasmic 1 (ACTB) OT1MCP2F ACTB_HUMAN Decreases Expression [75]
Cytochrome P450 1B1 (CYP1B1) OTYXFLSD CP1B1_HUMAN Decreases Expression [75]
Band 4.1-like protein 2 (EPB41L2) OT6UABPM E41L2_HUMAN Decreases Expression [76]
Receptor activity-modifying protein 1 (RAMP1) OT7UT2XB RAMP1_HUMAN Increases Expression [76]
Cystatin-F (CST7) OTQWZUVQ CYTF_HUMAN Decreases Expression [76]
Kelch repeat and BTB domain-containing protein 11 (KBTBD11) OTBOY3WH KBTBB_HUMAN Decreases Expression [76]
Aldehyde dehydrogenase 1A1 (ALDH1A1) OTCUWZKB AL1A1_HUMAN Increases Expression [76]
Carbonic anhydrase 2 (CA2) OTJRMUAG CAH2_HUMAN Decreases Expression [76]
Aldehyde dehydrogenase, mitochondrial (ALDH2) OTKJ9I3N ALDH2_HUMAN Increases Expression [76]
Tyrosine-protein kinase Fyn (FYN) OTLSLVZS FYN_HUMAN Increases Expression [76]
Procathepsin L (CTSL) OTYTUW29 CATL1_HUMAN Increases Expression [76]
Galectin-1 (LGALS1) OT8LDFWR LEG1_HUMAN Increases Expression [76]
SPARC (SPARC) OTPN90H0 SPRC_HUMAN Increases Expression [76]
Pro-cathepsin H (CTSH) OTLFL0DG CATH_HUMAN Increases Expression [76]
Non-secretory ribonuclease (RNASE2) OT8Z4FNE RNAS2_HUMAN Decreases Expression [76]
Transcriptional regulator ERG (ERG) OTOTX9VU ERG_HUMAN Increases Expression [76]
Tissue factor (F3) OT3MSU3B TF_HUMAN Decreases Expression [76]
Cytochrome c oxidase subunit 7A2, mitochondrial (COX7A2) OTVT146E CX7A2_HUMAN Decreases Expression [76]
Methylated-DNA--protein-cysteine methyltransferase (MGMT) OT40A9WH MGMT_HUMAN Decreases Expression [76]
Bactericidal permeability-increasing protein (BPI) OTNN9LJ5 BPI_HUMAN Decreases Expression [76]
Arachidonate 5-lipoxygenase-activating protein (ALOX5AP) OT0DH40W AL5AP_HUMAN Decreases Expression [76]
Interferon-induced GTP-binding protein Mx2 (MX2) OT05NF37 MX2_HUMAN Decreases Expression [76]
Amine oxidase A (MAOA) OT8NIWMQ AOFA_HUMAN Increases Expression [76]
Myeloblastin (PRTN3) OT72MHP7 PRTN3_HUMAN Decreases Expression [76]
Protein S100-P (S100P) OTJCXNJG S100P_HUMAN Decreases Expression [76]
Caspase-1 (CASP1) OTZ3YQFU CASP1_HUMAN Decreases Expression [76]
Myristoylated alanine-rich C-kinase substrate (MARCKS) OT7N056G MARCS_HUMAN Increases Expression [76]
Transmembrane 4 L6 family member 1 (TM4SF1) OTY0ECQN T4S1_HUMAN Increases Expression [76]
Intercellular adhesion molecule 3 (ICAM3) OTTZ5A5D ICAM3_HUMAN Decreases Expression [76]
P2Y purinoceptor 2 (P2RY2) OT47XN46 P2RY2_HUMAN Decreases Expression [76]
Glycine receptor subunit beta (GLRB) OTF37UG4 GLRB_HUMAN Increases Expression [76]
C-C chemokine receptor type 8 (CCR8) OTSCMH06 CCR8_HUMAN Decreases Expression [76]
Ras-related protein R-Ras2 (RRAS2) OT83NCEB RRAS2_HUMAN Increases Expression [76]
Bcl-2-interacting killer (BIK) OTTH1T3D BIK_HUMAN Decreases Expression [76]
Angiopoietin-1 (ANGPT1) OTVZ1NG3 ANGP1_HUMAN Increases Expression [76]
Fascin (FSCN1) OTTGIHTM FSCN1_HUMAN Increases Expression [76]
Pleckstrin homology-like domain family A member 2 (PHLDA2) OTMV9DPP PHLA2_HUMAN Increases Expression [76]
Testis-expressed protein 30 (TEX30) OT87WEPQ TEX30_HUMAN Decreases Expression [76]
Ras-related GTP-binding protein A (RRAGA) OTKISLG4 RRAGA_HUMAN Decreases Expression [76]
Cilium assembly protein DZIP1 (DZIP1) OTBVPO66 DZIP1_HUMAN Increases Expression [76]
RNA-binding protein with multiple splicing (RBPMS) OT1RDKR9 RBPMS_HUMAN Increases Expression [76]
Membrane-spanning 4-domains subfamily A member 3 (MS4A3) OT0CEJOO MS4A3_HUMAN Decreases Expression [76]
Rho GTPase-activating protein 7 (DLC1) OTP8LMCR RHG07_HUMAN Increases Expression [76]
MyoD family inhibitor domain-containing protein (MDFIC) OTSRYBWZ MDFIC_HUMAN Decreases Expression [76]
Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-12 (GNG12) OTOGF42G GBG12_HUMAN Increases Expression [76]
Cyclic AMP-dependent transcription factor ATF-5 (ATF5) OT03QCLM ATF5_HUMAN Decreases Expression [76]
PALM2-AKAP2 fusion protein (PALM2AKAP2) OTI618VF PLAK2_HUMAN Increases Expression [76]
Dihydropyrimidinase-related protein 4 (DPYSL4) OT3SBS2S DPYL4_HUMAN Increases Expression [56]
Integral membrane protein GPR137B (GPR137B) OT1CINQQ G137B_HUMAN Increases Expression [56]
Glutaminase kidney isoform, mitochondrial (GLS) OTGOZG2M GLSK_HUMAN Increases Expression [56]
Urokinase-type plasminogen activator (PLAU) OTX0QGKK UROK_HUMAN Increases Expression [56]
Ubiquitin-like protein ISG15 (ISG15) OT53QQ7N ISG15_HUMAN Increases Expression [56]
Early growth response protein 1 (EGR1) OTCP6XGZ EGR1_HUMAN Increases Expression [56]
Stomatin (STOM) OTC8R6EH STOM_HUMAN Increases Expression [56]
Cellular retinoic acid-binding protein 2 (CRABP2) OTY01V9G RABP2_HUMAN Increases Expression [56]
Tyrosine-protein kinase receptor UFO (AXL) OTKA2SUX UFO_HUMAN Increases Expression [56]
14-3-3 protein sigma (SFN) OTLJCZ1U 1433S_HUMAN Increases Expression [56]
Cyclin-dependent kinase inhibitor 1 (CDKN1A) OTQWHCZE CDN1A_HUMAN Increases Expression [56]
Tumor necrosis factor ligand superfamily member 9 (TNFSF9) OTV9L89D TNFL9_HUMAN Increases Expression [56]
Galectin-7 (LGALS7) OTMSVI7R LEG7_HUMAN Increases Expression [56]
Rho GDP-dissociation inhibitor 2 (ARHGDIB) OT9PD6CS GDIR2_HUMAN Increases Expression [56]
Epithelial membrane protein 1 (EMP1) OTSZHUHQ EMP1_HUMAN Increases Expression [56]
Epithelial membrane protein 3 (EMP3) OTODMJ1D EMP3_HUMAN Increases Expression [56]
Protein ripply3 (RIPPLY3) OT1HK35I DSCR6_HUMAN Increases Expression [56]
Pro-neuregulin-1, membrane-bound isoform (NRG1) OTZO6F1X NRG1_HUMAN Increases Expression [56]
Antigen peptide transporter 1 (TAP1) OTJL27PW TAP1_HUMAN Increases Expression [56]
Laminin subunit gamma-2 (LAMC2) OTJMTM72 LAMC2_HUMAN Increases Expression [56]
Filamin-C (FLNC) OT3F8J6Y FLNC_HUMAN Increases Expression [56]
Immediate early response gene 5 protein (IER5) OTJPTXMD IER5_HUMAN Increases Expression [56]
Keratin, type II cytoskeletal 80 (KRT80) OTAU54U3 K2C80_HUMAN Increases Expression [56]
Neuropilin and tolloid-like protein 2 (NETO2) OT0YAMC0 NETO2_HUMAN Increases Expression [56]
UDP-GalNAc:beta-1,3-N-acetylgalactosaminyltransferase 2 (B3GALNT2) OTOF6O2B B3GL2_HUMAN Increases Expression [56]
Phospholipase ABHD3 (ABHD3) OTH8P977 ABHD3_HUMAN Increases Expression [56]
Tumor necrosis factor receptor superfamily member 14 (TNFRSF14) OTB82PFO TNR14_HUMAN Increases Expression [56]
Major histocompatibility complex class I-related gene protein (MR1) OTZU3XX7 HMR1_HUMAN Increases Expression [56]
Tumor necrosis factor receptor superfamily member 27 (EDA2R) OTJLAIIH TNR27_HUMAN Increases Expression [56]
Stathmin-3 (STMN3) OT20F289 STMN3_HUMAN Increases Expression [56]
Solute carrier family 2, facilitated glucose transporter member 6 (SLC2A6) OTVUZCLG GTR6_HUMAN Increases Expression [56]
Endothelial protein C receptor (PROCR) OTRHED17 EPCR_HUMAN Increases Expression [56]
Serine/threonine-protein kinase Sgk1 (SGK1) OT301T1U SGK1_HUMAN Decreases Expression [57]
Interferon-related developmental regulator 1 (IFRD1) OT4SQMLQ IFRD1_HUMAN Decreases Expression [57]
Kinesin-like protein KIF21B (KIF21B) OTFXFIU3 KI21B_HUMAN Decreases Expression [57]
Large neutral amino acids transporter small subunit 3 (SLC43A1) OTQJQY3S LAT3_HUMAN Decreases Expression [57]
Cystatin-A (CSTA) OT1K68KE CYTA_HUMAN Decreases Expression [57]
Amino acid transporter heavy chain SLC3A2 (SLC3A2) OTBR33M9 4F2_HUMAN Decreases Expression [57]
Asparagine synthetase (ASNS) OT8R922G ASNS_HUMAN Decreases Expression [57]
Endoplasmic reticulum chaperone BiP (HSPA5) OTFUIRAO BIP_HUMAN Increases Expression [57]
Bifunctional methylenetetrahydrofolate dehydrogenase/cyclohydrolase, mitochondrial (MTHFD2) OT1LQSGX MTDC_HUMAN Decreases Expression [57]
CCAAT/enhancer-binding protein beta (CEBPB) OTM9MQIA CEBPB_HUMAN Decreases Expression [57]
Protein EVI2A (EVI2A) OTR8RUXQ EVI2A_HUMAN Decreases Expression [57]
Tumor necrosis factor receptor superfamily member 6 (FAS) OTP9XG86 TNR6_HUMAN Decreases Expression [57]
DnaJ homolog subfamily B member 1 (DNAJB1) OTCOSEVH DNJB1_HUMAN Increases Expression [57]
DNA damage-inducible transcript 3 protein (DDIT3) OTI8YKKE DDIT3_HUMAN Decreases Expression [57]
B-cell lymphoma 6 protein (BCL6) OTQAWWO1 BCL6_HUMAN Decreases Expression [57]
Radiation-inducible immediate-early gene IEX-1 (IER3) OTZJI5FZ IEX1_HUMAN Decreases Expression [57]
Cysteine--tRNA ligase, cytoplasmic (CARS1) OTOUZF6O SYCC_HUMAN Decreases Expression [57]
Sestrin-2 (SESN2) OT889IXY SESN2_HUMAN Decreases Expression [57]
Hydroxymethylglutaryl-CoA synthase, cytoplasmic (HMGCS1) OTCO26FV HMCS1_HUMAN Increases Expression [57]
DNA-binding protein inhibitor ID-2 (ID2) OT0U1D53 ID2_HUMAN Decreases Expression [57]
Early activation antigen CD69 (CD69) OTGJHSVP CD69_HUMAN Decreases Expression [57]
Transmembrane protein 267 (TMEM267) OTEAAVK7 TM267_HUMAN Decreases Expression [57]
Baculoviral IAP repeat-containing protein 3 (BIRC3) OT3E95KB BIRC3_HUMAN Decreases Expression [57]
Isopentenyl-diphosphate Delta-isomerase 1 (IDI1) OTGM06VJ IDI1_HUMAN Increases Expression [57]
N-arachidonyl glycine receptor (GPR18) OTL2VFIV GPR18_HUMAN Decreases Expression [57]
Nuclear receptor coactivator 7 (NCOA7) OT2CNBOG NCOA7_HUMAN Decreases Expression [57]
Alanine aminotransferase 2 (GPT2) OTS5VF7N ALAT2_HUMAN Decreases Expression [57]
Nanos homolog 1 (NANOS1) OT3UNZZY NANO1_HUMAN Increases Expression [57]
Heat shock protein 105 kDa (HSPH1) OTVRR73T HS105_HUMAN Increases Expression [57]
Insulin gene enhancer protein ISL-2 (ISL2) OT43PD2V ISL2_HUMAN Decreases Expression [57]
E3 ubiquitin-protein ligase pellino homolog 1 (PELI1) OTMLBCLC PELI1_HUMAN Decreases Expression [57]
Centriolar and ciliogenesis-associated protein HYLS1 (HYLS1) OT3SW5UC HYLS1_HUMAN Decreases Expression [57]
Tribbles homolog 3 (TRIB3) OTG5OS7X TRIB3_HUMAN Decreases Expression [57]
Glutathione-specific gamma-glutamylcyclotransferase 1 (CHAC1) OTJGE772 CHAC1_HUMAN Decreases Expression [57]
Transmembrane 6 superfamily member 1 (TM6SF1) OTQR4I2N TM6S1_HUMAN Decreases Expression [57]
Protein FAM107B (FAM107B) OT5RG4J0 F107B_HUMAN Decreases Expression [57]
Lysine-rich coiled-coil protein 1 (KRCC1) OTMMV6WZ KRCC1_HUMAN Decreases Expression [57]
DnaJ homolog subfamily B member 4 (DNAJB4) OTUD01BK DNJB4_HUMAN Increases Expression [57]
SLAM family member 5 (CD84) OTAY5B0F SLAF5_HUMAN Increases Expression [57]
Cystine/glutamate transporter (SLC7A11) OTKJ6PXW XCT_HUMAN Decreases Expression [57]
Nuclear factor erythroid 2-related factor 3 (NFE2L3) OT1MGXT0 NF2L3_HUMAN Decreases Expression [57]
Dual specificity protein phosphatase 10 (DUSP10) OTNG467B DUS10_HUMAN Decreases Expression [57]
Apoptotic protease-activating factor 1 (APAF1) OTJWIVY0 APAF_HUMAN Decreases Expression [58]
Transmembrane protease serine 2 (TMPRSS2) OTN44YQ5 TMPS2_HUMAN Increases Expression [77]
Growth arrest-specific protein 2 (GAS2) OT50JKXQ GAS2_HUMAN Increases Expression [78]
Lysine-specific histone demethylase 1A (KDM1A) OT85JXS5 KDM1A_HUMAN Increases Expression [79]
Slit homolog 1 protein (SLIT1) OT35RBNT SLIT1_HUMAN Decreases Expression [59]
DnaJ homolog subfamily B member 6 (DNAJB6) OTMHIIAN DNJB6_HUMAN Increases Expression [78]
Nuclear receptor subfamily 1 group I member 2 (NR1I2) OTC5U0N5 NR1I2_HUMAN Increases Activity [80]
Follitropin subunit beta (FSHB) OTGLS283 FSHB_HUMAN Increases Expression [81]
Thymidine kinase, cytosolic (TK1) OTY5JFM1 KITH_HUMAN Increases Mutagenesis [82]
Cellular tumor antigen p53 (TP53) OTIE1VH3 P53_HUMAN Increases Mutagenesis [83]
Endothelin-1 (EDN1) OTZCACEG EDN1_HUMAN Increases Expression [84]
ATP-dependent translocase ABCB1 (ABCB1) OTEJROBO MDR1_HUMAN Increases Expression [80]
Heme oxygenase 1 (HMOX1) OTC1W6UX HMOX1_HUMAN Decreases Expression [85]
Poly polymerase 1 (PARP1) OT310QSG PARP1_HUMAN Increases Cleavage [86]
Heat shock 70 kDa protein 1A (HSPA1A) OTKGIE76 HS71A_HUMAN Increases Expression [87]
Interleukin-8 (CXCL8) OTS7T5VH IL8_HUMAN Increases Expression [88]
Apoptosis regulator Bcl-2 (BCL2) OT9DVHC0 BCL2_HUMAN Increases Expression [89]
Histone H2AX (H2AX) OT18UX57 H2AX_HUMAN Increases Phosphorylation [90]
Natriuretic peptides B (NPPB) OTSN2IPY ANFB_HUMAN Increases Expression [84]
Troponin I, cardiac muscle (TNNI3) OT65E12V TNNI3_HUMAN Increases Expression [84]
Tumor necrosis factor alpha-induced protein 3 (TNFAIP3) OTVLI4DD TNAP3_HUMAN Increases Expression [91]
Growth arrest and DNA damage-inducible protein GADD45 alpha (GADD45A) OTDRV63V GA45A_HUMAN Increases Expression [58]
Endothelin receptor type B (EDNRB) OTLLZV3P EDNRB_HUMAN Increases Expression [59]
Insulin-like growth factor-binding protein 5 (IGFBP5) OTRE5V0C IBP5_HUMAN Decreases Expression [59]
DNA cytosine-5)-methyltransferase 1 (DNMT1) OTM2DGTK DNMT1_HUMAN Decreases Methylation [79]
Proteasome subunit alpha type-5 (PSMA5) OT38E6Y1 PSA5_HUMAN Increases Expression [78]
HLA class I histocompatibility antigen, alpha chain F (HLA-F) OT76CM19 HLAF_HUMAN Increases Expression [59]
Phospholipid hydroperoxide glutathione peroxidase GPX4 (GPX4) OTRAFFX2 GPX4_HUMAN Increases Expression [78]
Caspase-3 (CASP3) OTIJRBE7 CASP3_HUMAN Increases Expression [89]
Cytosolic purine 5'-nucleotidase (NT5C2) OTJMF66Z 5NTC_HUMAN Increases Expression [59]
Tumor protein D52 (TPD52) OTPKSK43 TPD52_HUMAN Decreases Expression [91]
Potassium voltage-gated channel subfamily KQT member 4 (KCNQ4) OT29B58J KCNQ4_HUMAN Decreases Expression [59]
Heterogeneous nuclear ribonucleoprotein K (HNRNPK) OTNPRM8U HNRPK_HUMAN Increases Expression [78]
Protein BTG2 (BTG2) OTZF6K1H BTG2_HUMAN Increases Expression [58]
Runt-related transcription factor 3 (RUNX3) OTITK1XD RUNX3_HUMAN Decreases Expression [59]
Calicin (CCIN) OTRFZOT0 CALI_HUMAN Increases Expression [78]
Programmed cell death protein 4 (PDCD4) OTZ6NXUX PDCD4_HUMAN Decreases Expression [91]
Ribonucleoside-diphosphate reductase subunit M2 B (RRM2B) OTE8GBUR RIR2B_HUMAN Increases Expression [92]
Partitioning defective 3 homolog (PARD3) OTH5BPLO PARD3_HUMAN Decreases Expression [59]
GATOR1 complex protein NPRL2 (NPRL2) OTOB10MO NPRL2_HUMAN Decreases Expression [59]
F-box/WD repeat-containing protein 7 (FBXW7) OTJXE4OT FBXW7_HUMAN Increases Expression [58]
Rho guanine nucleotide exchange factor 26 (ARHGEF26) OTX0U8PX ARHGQ_HUMAN Increases Expression [59]
G-protein coupled receptor 20 (GPR20) OTPCR8F7 GPR20_HUMAN Increases Expression [59]
Angiotensin-converting enzyme 2 (ACE2) OTTRZGU7 ACE2_HUMAN Decreases Expression [77]
Polyadenylate-binding protein-interacting protein 1 (PAIP1) OTL2F5T5 PAIP1_HUMAN Decreases Expression [59]
Large subunit GTPase 1 homolog (LSG1) OTDAXJ9L LSG1_HUMAN Decreases Expression [59]
Glyoxalase domain-containing protein 4 (GLOD4) OTBJKFXA GLOD4_HUMAN Decreases Expression [59]
DNA-directed DNA/RNA polymerase mu (POLM) OT0SRIP4 DPOLM_HUMAN Increases Expression [59]
Ubiquitin-like-conjugating enzyme ATG3 (ATG3) OT28VBVK ATG3_HUMAN Decreases Expression [59]
Regulator of telomere elongation helicase 1 (RTEL1) OTI3PJCT RTEL1_HUMAN Increases Expression [78]
FK506-binding protein-like (FKBPL) OTR9ND6K FKBPL_HUMAN Increases Expression [89]
Mitochondrial pyruvate carrier 2 (MPC2) OT0GHXGG MPC2_HUMAN Affects Response To Substance [60]
Krueppel-like factor 5 (KLF5) OT1ABI9N KLF5_HUMAN Affects Response To Substance [60]
Galactocerebrosidase (GALC) OT1F6BZK GALC_HUMAN Affects Response To Substance [60]
Granulocyte-macrophage colony-stimulating factor (CSF2) OT1M7D28 CSF2_HUMAN Affects Activity [93]
Superoxide dismutase (SOD1) OT39TA1L SODC_HUMAN Increases ADR [55]
Krueppel-like factor 4 (KLF4) OT4O9RQW KLF4_HUMAN Decreases Response To Substance [94]
D-beta-hydroxybutyrate dehydrogenase, mitochondrial (BDH1) OT62RL5P BDH_HUMAN Affects Response To Substance [60]
Melanoma-associated antigen D1 (MAGED1) OT6EOLFC MAGD1_HUMAN Affects Response To Substance [60]
Prostaglandin G/H synthase 2 (PTGS2) OT75U9M4 PGH2_HUMAN Affects Response To Substance [60]
Pro-adrenomedullin (ADM) OT7T0TA4 ADML_HUMAN Affects Response To Substance [60]
Peptidyl-prolyl cis-trans isomerase FKBP1B (FKBP1B) OT8CMPB2 FKB1B_HUMAN Affects Response To Substance [60]
L-lactate dehydrogenase B chain (LDHB) OT9B1CT3 LDHB_HUMAN Affects Response To Substance [60]
Epsilon-sarcoglycan (SGCE) OT9F17JB SGCE_HUMAN Affects Response To Substance [60]
Caspase-8 (CASP8) OTA8TVI8 CASP8_HUMAN Increases Response To Substance [95]
Aldehyde dehydrogenase, dimeric NADP-preferring (ALDH3A1) OTAYZZE6 AL3A1_HUMAN Affects Response To Substance [96]
Sterol O-acyltransferase 1 (SOAT1) OTB4Y5RJ SOAT1_HUMAN Affects Response To Substance [60]
Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) OTB97VIK IF2B3_HUMAN Affects Response To Substance [60]
Cochlin (COCH) OTBEHD89 COCH_HUMAN Affects Response To Substance [60]
Fibronectin type III domain-containing protein 3B (FNDC3B) OTBILGDR FND3B_HUMAN Affects Response To Substance [60]
Tropomyosin alpha-1 chain (TPM1) OTD73X6R TPM1_HUMAN Affects Response To Substance [60]
Very long chain fatty acid elongase 2 (ELOVL2) OTDAF6U3 ELOV2_HUMAN Affects Response To Substance [60]
Glutathione peroxidase 1 (GPX1) OTE2O72Q GPX1_HUMAN Increases ADR [55]
Protein AF1q (MLLT11) OTG5RVHC AF1Q_HUMAN Decreases Response To Substance [97]
Troponin I, fast skeletal muscle (TNNI2) OTGGZFSC TNNI2_HUMAN Increases ADR [55]
Multidrug resistance-associated protein 1 (ABCC1) OTGUN89S MRP1_HUMAN Decreases Response To Substance [98]
Tomoregulin-1 (TMEFF1) OTH6M3CH TEFF1_HUMAN Affects Response To Substance [60]
DNA damage-inducible transcript 4 protein (DDIT4) OTHY8SY4 DDIT4_HUMAN Affects Response To Substance [60]
Ribosomal protein S6 kinase alpha-2 (RPS6KA2) OTIOYUSU KS6A2_HUMAN Affects Response To Substance [60]
Superoxide dismutase , mitochondrial (SOD2) OTIWXGZ9 SODM_HUMAN Affects Response To Substance [99]
Insulin-like growth factor-binding protein 3 (IGFBP3) OTIX63TX IBP3_HUMAN Affects Response To Substance [60]
Osteopontin (SPP1) OTJGC23Y OSTP_HUMAN Affects Response To Substance [60]
Heat shock cognate 71 kDa protein (HSPA8) OTJI2RCI HSP7C_HUMAN Affects Response To Substance [60]
Nidogen-1 (NID1) OTKLBLS6 NID1_HUMAN Affects Response To Substance [60]
Glutathione reductase, mitochondrial (GSR) OTM2TUYM GSHR_HUMAN Increases ADR [55]
Homeobox protein Hox-A1 (HOXA1) OTMSOJ7D HXA1_HUMAN Affects Response To Substance [60]
Trypsin-3 (PRSS3) OTN3S5YB TRY3_HUMAN Affects Response To Substance [60]
Melanoma-associated antigen D4 (MAGED4B) OTO37U7W MAGD4_HUMAN Affects Response To Substance [60]
Opsin-3 (OPN3) OTON6BFU OPN3_HUMAN Affects Response To Substance [60]
Interleukin-1 alpha (IL1A) OTPSGILV IL1A_HUMAN Affects Response To Substance [100]
Complement factor I (CFI) OTQYYX0P CFAI_HUMAN Affects Response To Substance [60]
Heat shock-related 70 kDa protein 2 (HSPA2) OTSDET7B HSP72_HUMAN Affects Response To Substance [60]
Cytochrome P450 3A5 (CYP3A5) OTSXFBXB CP3A5_HUMAN Affects Response To Substance [101]
Max-interacting protein 1 (MXI1) OTUQ9E0D MXI1_HUMAN Affects Response To Substance [60]
Glycogen debranching enzyme (AGL) OTWBM7WY GDE_HUMAN Affects Response To Substance [60]
Myosin-10 (MYH10) OTXN2WXS MYH10_HUMAN Affects Response To Substance [60]
Sal-like protein 1 (SALL1) OTYYZGLH SALL1_HUMAN Affects Response To Substance [60]
------------------------------------------------------------------------------------
⏷ Show the Full List of 225 DOT(s)

References

1 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2 Gefitinib FDA Label
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4941).
4 Cyclophosphamide FDA Label
5 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7154).
6 Synergistic antitumor effect of S-1 and the epidermal growth factor receptor inhibitor gefitinib in non-small cell lung cancer cell lines: role of gefitinib-induced down-regulation of thymidylate synthase. Mol Cancer Ther. 2008 Mar;7(3):599-606.
7 Frankincense myrrh attenuates hepatocellular carcinoma by regulating tumor blood vessel development through multiple epidermal growth factor receptor-mediated signaling pathways. World J Gastrointest Oncol. 2022 Feb 15;14(2):450-477. doi: 10.4251/wjgo.v14.i2.450.
8 EGFR inhibitors enhanced the susceptibility to NK cell-mediated lysis of lung cancer cells. J Immunother. 2011 May;34(4):372-81. doi: 10.1097/CJI.0b013e31821b724a.
9 Overcoming acquired resistance of gefitinib in lung cancer cells without T790M by AZD9291 or Twist1 knockdown in vitro and in vivo. Arch Toxicol. 2019 Jun;93(6):1555-1571. doi: 10.1007/s00204-019-02453-2. Epub 2019 Apr 16.
10 DNA repair gene polymorphisms and benefit from gefitinib in never-smokers with lung adenocarcinoma. Cancer. 2011 Jul 15;117(14):3201-8. doi: 10.1002/cncr.25863. Epub 2011 Jan 24.
11 Gefitinib ('Iressa', ZD1839) and new epidermal growth factor receptor inhibitors. Br J Cancer. 2004 Feb 9;90(3):566-72.
12 Gefitinib-phenytoin interaction is not correlated with the C-erythromycin breath test in healthy male volunteers. Br J Clin Pharmacol. 2009 Aug;68(2):226-37.
13 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
14 Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. Clin Cancer Res. 2013 Mar 15;19(6):1458-66.
15 Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes. Clin Cancer Res. 2007 Jun 15;13(12):3731-7.
16 Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol. Clin Pharmacokinet. 2005;44(10):1067-81.
17 Pharmacogenetics of ABCG2 and adverse reactions to gefitinib. J Natl Cancer Inst. 2006 Dec 6;98(23):1739-42.
18 Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival. Cancer Res. 2006 Jun 1;66(11):5542-8. doi: 10.1158/0008-5472.CAN-05-4620.
19 Identification of genes linked to gefitinib treatment in prostate cancer cell lines with or without resistance to androgen: a clue to application of gefitinib to hormone-resistant prostate cancer. Oncol Rep. 2006 Jun;15(6):1453-60.
20 Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development. Toxicol Sci. 2010 Dec; 118(2):485-500.
21 Effects and mechanisms of betulinic acid on improving EGFR TKI-resistance of lung cancer cells. Environ Toxicol. 2018 Nov;33(11):1153-1159.
22 Antiproliferative effects of gefitinib are associated with suppression of E2F-1 expression and telomerase activity. Anticancer Res. 2006 Sep-Oct;26(5A):3387-91.
23 Leptomycin B reduces primary and acquired resistance of gefitinib in lung cancer cells. Toxicol Appl Pharmacol. 2017 Nov 15;335:16-27. doi: 10.1016/j.taap.2017.09.017. Epub 2017 Sep 21.
24 EGFR tyrosine kinase inhibitors activate autophagy as a cytoprotective response in human lung cancer cells. PLoS One. 2011;6(6):e18691. doi: 10.1371/journal.pone.0018691. Epub 2011 Jun 2.
25 ZD1839 induces p15INK4b and causes G1 arrest by inhibiting the mitogen-activated protein kinase/extracellular signal-regulated kinase pathway. Mol Cancer Ther. 2007 May;6(5):1579-87. doi: 10.1158/1535-7163.MCT-06-0814.
26 Reactive metabolite of gefitinib activates inflammasomes: implications for gefitinib-induced idiosyncratic reaction. J Toxicol Sci. 2020;45(11):673-680. doi: 10.2131/jts.45.673.
27 Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis. Chem Res Toxicol. 2015 May 18;28(5):927-34. doi: 10.1021/tx5005248. Epub 2015 Apr 3.
28 Bidirectional cross talk between ERalpha and EGFR signalling pathways regulates tamoxifen-resistant growth. Breast Cancer Res Treat. 2006 Mar;96(2):131-46. doi: 10.1007/s10549-005-9070-2. Epub 2005 Oct 27.
29 Epidermal growth factor receptor activity determines response of colorectal cancer cells to gefitinib alone and in combination with chemotherapy. Clin Cancer Res. 2005 Oct 15;11(20):7480-9. doi: 10.1158/1078-0432.CCR-05-0328.
30 Implication of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinib. Clin Cancer Res. 2007 May 1;13(9):2795-803. doi: 10.1158/1078-0432.CCR-06-2077.
31 Evidence of securin-mediated resistance to gefitinib-induced apoptosis in human cancer cells. Chem Biol Interact. 2013 Apr 25;203(2):412-22. doi: 10.1016/j.cbi.2013.03.011. Epub 2013 Mar 22.
32 Crosstalk between alveolar macrophages and alveolar epithelial cells/fibroblasts contributes to the pulmonary toxicity of gefitinib. Toxicol Lett. 2021 Mar 1;338:1-9. doi: 10.1016/j.toxlet.2020.11.011. Epub 2020 Nov 25.
33 Cytotoxicity of 34 FDA approved small-molecule kinase inhibitors in primary rat and human hepatocytes. Toxicol Lett. 2018 Jul;291:138-148. doi: 10.1016/j.toxlet.2018.04.010. Epub 2018 Apr 12.
34 Growth of hormone-dependent MCF-7 breast cancer cells is promoted by constitutive caveolin-1 whose expression is lost in an EGF-R-mediated manner during development of tamoxifen resistance. Breast Cancer Res Treat. 2010 Feb;119(3):575-91. doi: 10.1007/s10549-009-0355-8. Epub 2009 Mar 15.
35 Dihydromyricetin suppresses tumor growth via downregulation of the EGFR/Akt/survivin signaling pathway. J Biochem Mol Toxicol. 2023 Jun;37(6):e23328. doi: 10.1002/jbt.23328. Epub 2023 Feb 19.
36 The anti-cancer drug gefitinib accelerates Fas-mediated apoptosis by enhancing caspase-8 activation in cancer cells. J Toxicol Sci. 2019;44(6):435-440. doi: 10.2131/jts.44.435.
37 Autophagy Inhibition Overcomes the Antagonistic Effect Between Gefitinib and Cisplatin in Epidermal Growth Factor Receptor Mutant Non--Small-Cell Lung Cancer Cells. Clin Lung Cancer. 2015 Sep;16(5):e55-66. doi: 10.1016/j.cllc.2015.03.006. Epub 2015 Apr 2.
38 Nrf2 but not autophagy inhibition is associated with the survival of wild-type epidermal growth factor receptor non-small cell lung cancer cells. Toxicol Appl Pharmacol. 2016 Nov 1;310:140-149. doi: 10.1016/j.taap.2016.09.010. Epub 2016 Sep 14.
39 Association of CYP1A1 and CYP1B1 inhibition in in vitro assays with drug-induced liver injury. J Toxicol Sci. 2021;46(4):167-176. doi: 10.2131/jts.46.167.
40 Susceptibility to natural killer cell-mediated lysis of colon cancer cells is enhanced by treatment with epidermal growth factor receptor inhibitors through UL16-binding protein-1 induction. Cancer Sci. 2012 Jan;103(1):7-16. doi: 10.1111/j.1349-7006.2011.02109.x. Epub 2011 Nov 15.
41 Combined tamoxifen and gefitinib in non-small cell lung cancer shows antiproliferative effects. Biomed Pharmacother. 2010 Feb;64(2):88-92. doi: 10.1016/j.biopha.2009.06.010. Epub 2009 Oct 23.
42 Inorganic arsenic exposure promotes malignant progression by HDAC6-mediated down-regulation of HTRA1. J Appl Toxicol. 2023 Aug;43(8):1214-1224. doi: 10.1002/jat.4457. Epub 2023 Mar 11.
43 A high-throughput screen for teratogens using human pluripotent stem cells. Toxicol Sci. 2014 Jan;137(1):76-90. doi: 10.1093/toxsci/kft239. Epub 2013 Oct 23.
44 Inhibition of SREBP increases gefitinib sensitivity in non-small cell lung cancer cells. Oncotarget. 2016 Aug 9;7(32):52392-52403.
45 The K-Ras effector p38 MAPK confers intrinsic resistance to tyrosine kinase inhibitors by stimulating EGFR transcription and EGFR dephosphorylation. J Biol Chem. 2017 Sep 8;292(36):15070-15079. doi: 10.1074/jbc.M117.779488. Epub 2017 Jul 24.
46 Slug confers resistance to the epidermal growth factor receptor tyrosine kinase inhibitor. Am J Respir Crit Care Med. 2011 Apr 15;183(8):1071-9. doi: 10.1164/rccm.201009-1440OC. Epub 2010 Oct 29.
47 Identification of protein expression alterations in gefitinib-resistant human lung adenocarcinoma: PCNT and mPR play key roles in the development of gefitinib-associated resistance. Toxicol Appl Pharmacol. 2015 Nov 1;288(3):359-73. doi: 10.1016/j.taap.2015.08.008. Epub 2015 Aug 20.
48 Induction of CYP1A1 increases gefitinib-induced oxidative stress and apoptosis in A549 cells. Toxicol In Vitro. 2017 Oct;44:36-43.
49 Prediction of sensitivity of advanced non-small cell lung cancers to gefitinib (Iressa, ZD1839). Hum Mol Genet. 2004 Dec 15;13(24):3029-43. doi: 10.1093/hmg/ddh331. Epub 2004 Oct 20.
50 The transcription factor FOXO3a is a crucial cellular target of gefitinib (Iressa) in breast cancer cells. Mol Cancer Ther. 2007 Dec;6(12 Pt 1):3169-79. doi: 10.1158/1535-7163.MCT-07-0507.
51 Aurora-A promotes gefitinib resistance via a NF-B signaling pathway in p53 knockdown lung cancer cells. Biochem Biophys Res Commun. 2011 Feb 11;405(2):168-72. doi: 10.1016/j.bbrc.2011.01.001. Epub 2011 Jan 7.
52 BIM induction of apoptosis triggered by EGFR-sensitive and resistance cell lines of non-small-cell lung cancer. Med Oncol. 2011 Jun;28(2):572-7. doi: 10.1007/s12032-010-9470-y. Epub 2010 Mar 17.
53 E3 ubiquitin ligase RNF180 reduces sensitivity of triple-negative breast cancer cells to Gefitinib by downregulating RAD51. Chem Biol Interact. 2022 Feb 25;354:109798. doi: 10.1016/j.cbi.2022.109798. Epub 2022 Jan 6.
54 Increases of amphiregulin and transforming growth factor-alpha in serum as predictors of poor response to gefitinib among patients with advanced non-small cell lung cancers. Cancer Res. 2005 Oct 15;65(20):9176-84. doi: 10.1158/0008-5472.CAN-05-1556.
55 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
56 Genomic profiling uncovers a molecular pattern for toxicological characterization of mutagens and promutagens in vitro. Toxicol Sci. 2011 Jul;122(1):185-97.
57 Transcriptome-based functional classifiers for direct immunotoxicity. Arch Toxicol. 2014 Mar;88(3):673-89.
58 Comparison of Drug Metabolism and Its Related Hepatotoxic Effects in HepaRG, Cryopreserved Human Hepatocytes, and HepG2 Cell Cultures. Biol Pharm Bull. 2018 May 1;41(5):722-732. doi: 10.1248/bpb.b17-00913. Epub 2018 Feb 14.
59 Effect of nephrotoxicants and hepatotoxicants on gene expression profile in human peripheral blood mononuclear cells. Biochem Biophys Res Commun. 2010 Oct 15;401(2):245-50. doi: 10.1016/j.bbrc.2010.09.039. Epub 2010 Sep 16.
60 Gene expression profiling of 30 cancer cell lines predicts resistance towards 11 anticancer drugs at clinically achieved concentrations. Int J Cancer. 2006 Apr 1;118(7):1699-712. doi: 10.1002/ijc.21570.
61 O6-methylguanine-DNA methyltransferase activity and sensitivity to cyclophosphamide and cisplatin in human lung tumor xenografts. Int J Cancer. 1998 Sep 11;77(6):919-22.
62 Interaction of oxazaphosphorines with multidrug resistance-associated protein 4 (MRP4). AAPS J. 2010 Sep;12(3):300-8.
63 Effects of ketoconazole on cyclophosphamide metabolism: evaluation of CYP3A4 inhibition effect using the in vitro and in vivo models. Exp Anim. 2018 Feb 9;67(1):71-82.
64 Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles. Drug Metab Dispos. 1999 Jun;27(6):655-66.
65 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
66 Enhanced cyclophosphamide and ifosfamide activation in primary human hepatocyte cultures: response to cytochrome P-450 inducers and autoinduction by oxazaphosphorines. Cancer Res. 1997 May 15;57(10):1946-54.
67 CYP2C9 polymorphisms in human tumors. Anticancer Res. 2006 Jan-Feb;26(1A):299-305.
68 The effect of cyclophosphamide with and without dexamethasone on cytochrome P450 3A4 and 2B6 in human hepatocytes. Drug Metab Dispos. 2002 Jul;30(7):814-22.
69 Cytochrome P450 pharmacogenetics and cancer. Oncogene. 2006 Mar 13;25(11):1679-91.
70 Identification of the polymorphically expressed CYP2C19 and the wild-type CYP2C9-ILE359 allele as low-Km catalysts of cyclophosphamide and ifosfamide activation. Pharmacogenetics. 1997 Jun;7(3):211-21.
71 Nuclear receptor mediated induction of cytochrome P450 3A4 by anticancer drugs: a key role for the pregnane X receptor. Cancer Chemother Pharmacol. 2009 Jun;64(1):35-43.
72 Sustained P450 expression and prodrug activation in bolus cyclophosphamide-treated cultured tumor cellsImpact of prodrug schedule on P450 gene-directed enzyme prodrug therapy. Cancer Gene Ther. 2003 Aug;10(8):571-82.
73 Establishment of the transformants expressing human cytochrome P450 subtypes in HepG2, and their applications on drug metabolism and toxicology. Toxicol In Vitro. 2001 Jun;15(3):245-56.
74 Qualitative defects of pseudocholinesterase activity. Anaesthesia. 1967 Jan;22(1):55-68.
75 Effect of cyclophosphamide on gene expression of cytochromes p450 and beta-actin in the HL-60 cell line. Eur J Pharmacol. 2002 Aug 9;449(3):197-205.
76 Comparative gene expression analysis of a chronic myelogenous leukemia cell line resistant to cyclophosphamide using oligonucleotide arrays and response to tyrosine kinase inhibitors. Leuk Res. 2007 Nov;31(11):1511-20.
77 Effect of common medications on the expression of SARS-CoV-2 entry receptors in liver tissue. Arch Toxicol. 2020 Dec;94(12):4037-4041. doi: 10.1007/s00204-020-02869-1. Epub 2020 Aug 17.
78 Chronic cyclophosphamide exposure alters the profile of rat sperm nuclear matrix proteins. Biol Reprod. 2007 Aug;77(2):303-11. doi: 10.1095/biolreprod.107.060244. Epub 2007 May 2.
79 Cyclophosphamide perturbs cytosine methylation in Jurkat-T cells through LSD1-mediated stabilization of DNMT1 protein. Chem Res Toxicol. 2011 Nov 21;24(11):2040-3. doi: 10.1021/tx2003849. Epub 2011 Nov 1.
80 PXR-mediated induction of P-glycoprotein by anticancer drugs in a human colon adenocarcinoma-derived cell line. Cancer Chemother Pharmacol. 2010 Sep;66(4):765-71. doi: 10.1007/s00280-009-1221-4. Epub 2009 Dec 30.
81 Suppression of spermatogenesis in patients with Beh?et's disease treated with cyclophosphamide and colchicine. Fertil Steril. 1981 Jul;36(1):76-80. doi: 10.1016/s0015-0282(16)45622-0.
82 Development of an integrated assay in human TK6 cells to permit comprehensive genotoxicity analysis in vitro. Mutat Res Genet Toxicol Environ Mutagen. 2020 Jan;849:503129. doi: 10.1016/j.mrgentox.2019.503129. Epub 2019 Dec 27.
83 p53 mutations in cyclophosphamide-associated bladder cancer. Cancer Epidemiol Biomarkers Prev. 1998 May;7(5):397-403.
84 Cardiac toxicity of high-dose cyclophosphamide in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplantation. Int J Hematol. 2007 Jun;85(5):408-14. doi: 10.1532/IJH97.E0620.
85 Protein assay for heme oxygenase-1 (HO-1) induced by chemicals in HepG2 cells. J Toxicol Sci. 2009 Dec;34(6):709-14. doi: 10.2131/jts.34.709.
86 Bortezomib is synergistic with rituximab and cyclophosphamide in inducing apoptosis of mantle cell lymphoma cells in vitro and in vivo. Leukemia. 2008 Jan;22(1):179-85. doi: 10.1038/sj.leu.2404959. Epub 2007 Sep 27.
87 Induction of hsp 70 in HepG2 cells in response to hepatotoxicants. Toxicol Appl Pharmacol. 1996 Nov;141(1):117-23.
88 Profiling the immunotoxicity of chemicals based on in vitro evaluation by a combination of the Multi-ImmunoTox assay and the IL-8 Luc assay. Arch Toxicol. 2018 Jun;92(6):2043-2054. doi: 10.1007/s00204-018-2199-7. Epub 2018 Mar 29.
89 The differential effects of cyclophosphamide, epirubicin and 5-fluorouracil on apoptotic marker (CPP-32), pro-apoptotic protein (p21(WAF-1)) and anti-apoptotic protein (bcl-2) in breast cancer cells. Breast Cancer Res Treat. 2003 Aug;80(3):239-44. doi: 10.1023/A:1024995202135.
90 Distinct Orchestration and Dynamic Processes on -H2AX and p-H3 for Two Major Types of Genotoxic Chemicals Revealed by Mass Spectrometry Analysis. Chem Res Toxicol. 2020 Aug 17;33(8):2108-2119. doi: 10.1021/acs.chemrestox.0c00104. Epub 2020 Jun 17.
91 Human embryonic stem cell derived hepatocyte-like cells as a tool for in vitro hazard assessment of chemical carcinogenicity. Toxicol Sci. 2011 Dec;124(2):278-90. doi: 10.1093/toxsci/kfr225. Epub 2011 Aug 27.
92 Validation of a genotoxicity test based on p53R2 gene expression in human lymphoblastoid cells. Mutat Res. 2011 Sep 18;724(1-2):76-85. doi: 10.1016/j.mrgentox.2011.06.003. Epub 2011 Jun 17.
93 Reduction of plasma fibrinolytic activity following high-dose cyclophosphamide is neutralized in vivo by GM-CSF administration. Haematologica. 1993 Mar-Apr;78(2):105-10.
94 Inhibition of glutathione synthesis reverses Krppel-like factor 4-mediated cisplatin resistance. Cancer Chemother Pharmacol. 2012 Feb;69(2):377-85. doi: 10.1007/s00280-011-1708-7. Epub 2011 Jul 22.
95 Important role of caspase-8 for chemosensitivity of ALL cells. Clin Cancer Res. 2011 Dec 15;17(24):7605-13. doi: 10.1158/1078-0432.CCR-11-0513. Epub 2011 Oct 18.
96 Relations between polymorphisms in drug-metabolising enzymes and toxicity of chemotherapy with cyclophosphamide, thiotepa and carboplatin. Pharmacogenet Genomics. 2008 Nov;18(11):1009-15. doi: 10.1097/FPC.0b013e328313aaa4.
97 The evaluation of Cannabidiol's effect on the immunotherapy of Burkitt lymphoma. Biochem Biophys Res Commun. 2019 Nov 26;520(1):225-230. doi: 10.1016/j.bbrc.2019.10.001. Epub 2019 Oct 3.
98 [Establishment of MRP-overexpression subline of bladder carcinoma and its MDR phenotype]. Zhonghua Zhong Liu Za Zhi. 2000 Jul;22(4):273-5.
99 Manganese superoxide dismutase polymorphism, treatment-related toxicity and disease-free survival in SWOG 8897 clinical trial for breast cancer. Breast Cancer Res Treat. 2010 Nov;124(2):433-9. doi: 10.1007/s10549-010-0840-0. Epub 2010 Mar 23.
100 T-889C IL-1alpha promoter polymorphism influences the response to oral cyclophosphamide in scleroderma patients with alveolitis. Clin Rheumatol. 2007 Jan;26(1):88-91. doi: 10.1007/s10067-006-0308-0. Epub 2006 Apr 25.
101 Associations between drug metabolism genotype, chemotherapy pharmacokinetics, and overall survival in patients with breast cancer. J Clin Oncol. 2005 Sep 1;23(25):6117-25. doi: 10.1200/JCO.2005.06.075. Epub 2005 Aug 8.